Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance after tandem autologous and non-myeloablative allogeneic stem cell transplantation in multiple myeloma
NL-OMON27419Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by HOVON. Primary endpoint: Progression-free survival. Started Dec 2007; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON27419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27419.